ReviewInternational journal of molecular sciences2025
Insights into Patient Heterogeneity in Sjögren's Disease.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical and Ultrasonographic Characterization of Proposed Sjögren's Disease Phenotypes in a Korean Longitudinal Cohort.Journal of clinical medicine · 2026Article
- FASN-mediated metabolic reprogramming drives CD4Arthritis research & therapy · 2026Article
- Shengjiangsan Upregulates miR-328-3p to Inhibit MAP3K9 in the Treatment of Sjogren Disease: A Bioinformatics Analysis.Journal of inflammation research · 2026Article
- Keratoconjunctivitis Sicca in Sjögren Disease: Diagnostic Challenges and Therapeutic Advances.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Sjögren's disease is multi-system autoimmune disease characterized by dryness of mucosal surfaces, fatigue, and pain. Heterogeneity among patients is a major obstacle for timely diagnosis, management of patients, and clinical trial design. Strategies for patient stratification are therefore desperately needed. In this review, we aimed to summarize current stratification approaches. Two major approaches for patient stratification are currently used. The first one is based on patient-reported symptoms and the subsequent analysis of the clinical and biological characteristics defining the identified clusters. The second strategy is based on the molecular stratification of patients, followed by the analysis of clinical characteristics along with other biological data. The combination of different approaches holds great potential to improve the recognition of patient subgroups and the development of tailored therapies. The current literature suggests that three to four subgroups of patients with SjD exist. Whether these subgroups represent disease stages or disease endotypes is still a matter of debate and will be a topic of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.